Victoria removes roadblocks for medicinal cannabis
Another day, another roadblock removed to medical cannabis acceptance with the Victorian government clearing the way for legal access in “exceptional circumstances”.
Thanks to a bill which passed Victorian parliament earlier this week, patients and their families will be able to legally access medical cannabis – with an initial focus on children with severe epilepsy.
The Victorian government had previously flagged increased access to synthetic medical cannabis trials for those suffering epilepsy – but the latest bill effectively creates a framework for patients to access medical cannabis for the first time.
At this stage, patients should be able to access medical cannabis from early 2017.
State health minister Jill Hennessy said the bill would alleviate suffering she had witnessed first-hand.
“It is absolutely heart-breaking to see families having to choose between breaking the law and watching their children suffer – and now, thanks to our ground-breaking legislation, they won’t have to,” Hennessey said in a statement.
In addition to increased access, the Victorian government will move to establish an Office of Medicinal Cannabis to help oversee manufacture and all clinical aspects of the bill framework.
As part of this push, the Victorian government will create an advisory body to help provide advice on which products would be available under the laws and other matters.
It also flagged the possibility of widening the scope of who would be able to access the products in the future.
In February the Australian senate passed a bill which essentially put medical cannabis into the same restricted class of drugs as morphine – rather than being classed as an illicit drug.
The way for a national regulator has now been paved to be set up to audit companies which wish to grow medical cannabis in Australia, extracting cannabidiol to use in medical products.
At the time, health minister Susan Ley called it the “missing link” in Australian regulation of medical cannabis products.
Previoulsy, patients had a confusing combination of ways to access medical cannabis products – some of which have been shown to help multiple sclerosis, epilepsy and some cancers.
In the past, Australians had to import products but were faced with export barriers in place in other countries.
Having a local supply of Australian made and manufactured medical cannabis products has significant potential for patients who could benefit from medical cannabis products.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.